Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Johnson, JA; Caudle, KE; Gong, Li; Whirl‐Carrillo, Michelle; Stein, Catherine M.; Scott, Stuart A.; Lee, MT; Gage, Brian F.; Kimmel, SE; Perera, Minoli A.; Anderson, JL; Pirmohamed, Munir; Klein, Teri E.; Limdi, NA; Cavallari, Larisa H.; Wadelius, Mia

doi:10.1002/cpt.668

articleClinical Pharmacology & TherapeuticsFeb 15, 2017BRONZE OA

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

JJJA Johnson KCKE Caudle LGLi Gong MWMichelle Whirl‐Carrillo CMCatherine M. Stein

University of Florida · St. Jude Children's Research Hospital · +16 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Citation impact

689

total citations

FWCI: 69.81
Percentile: 100%
References: 44

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Pharmacogenetics
Dosing
Warfarin
Medicine
Guideline
VKORC1
CYP2C9
Pharmacology

UN Sustainable Development Goals

Partnerships for the goals

No related works found for this paper.